MedTrace Logo

TRT for ES-SCLC After First Line Treatment With Immune Checkpoint Inhibitors

NCT05544149 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2022-09-16

No results posted yet for this study

Summary

To Evaluate the Safety and Efficacy of Thoracic Radiotherapy for?ES-SCLC After First Line Treatment with Immune Checkpoint Inhibitors.

Conditions

  • SCLC,Extensive Stage

Interventions

RADIATION

Thoracic radiotherapy

Thoracic radiotherapy for ES-SCLC after first line immunecheckpoint inhibitors

Sponsors & Collaborators

  • Zhejiang Cancer Hospital

    lead OTHER

Principal Investigators

  • Xiaojing Lai · Department of Thoracic Radiotherapy, Zhejiang Cancer Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-01
Primary Completion
2024-08-30
Completion
2025-08-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05544149 on ClinicalTrials.gov